Biopharma R&D Productivity And Growth 2016: Innovation Performance Improves
Executive Summary
Catenion updates its annual list of the year's top pharma R&D performers, based on R&D productivity and growth. This year Regeneron shoots to the top and Gilead drops to third place.
You may also be interested in...
Biopharma R&D Productivity And Growth 2017: Big Pharma Closes The Gap
Catenion updates its annual list of the year's top pharma R&D performers. R&D productivity declined for the first time since 2014. Mid pharmas continue to dominate the top 10, but big pharmas are making inroads.
When It Comes To Pharma R&D ROI, Mid Pharma Companies Outperform
Datamonitor Healthcare's measurement of pharma R&D return on investment finds that Mid Pharma companies outperform on an ROI index. The second in a two-part series evaluating R&D productivity.
External R&D Is Up, But Which Companies Are Reaping The Most Benefit?
Amgen, Novartis and Lilly are projected to increase sales from externally sourced assets in the coming years, according to a Datamonitor Healthcare analysis, while other big pharma – including frequent acquirer Pfizer and smaller-deal-oriented Bristol – are expected to see that ratio decline compared to sales of internally developed drugs.